semaglutide fda label Oral Wegovy approved for obesity management by on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) A big win for Wegovy:

This process typically takes several years from the start of phase 3 trials

Reduced Food Cravings: Clinical studies using functional MRI scans have shown that patients on semaglutide or liraglutide exhibit lower activation in reward-related brain regions when exposed to high-calorie foods

Barriers to Over-the-Counter Approval for Weight Loss Medications The FDA's approval pathway for over-the-counter drugs demands significantly higher evidence thresholds than prescription medications

In this regard, it is important to mention that Retatrutide is contraindicated to patients who have experienced recurrent or severe hypoglycemia episodes